Filing summary: Transgenomic, Inc. Form 10-Q
Entity note: The filing provided is for Transgenomic, Inc. (ticker TBIO), not Precipio, Inc. It covers the quarter ended June 30, 2014, and was signed August 8, 2014. Unless noted otherwise, financial amounts below are in millions of dollars.
Business context and reporting period
Transgenomic operated two segments: Laboratory Services, including patient genetic testing and biomarker research services, and Genetic Assays and Platforms, including instruments, assays, and consumables. The company emphasized its ICE COLD-PCR technology and personalized-medicine strategy. The filing notes a one-for-twelve reverse stock split effective January 27, 2014; share and per-share figures were adjusted accordingly.
Financial performance and position
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Net sales | $6.764 | $7.306 | $13.015 | $14.680 |
| Gross profit / margin | $2.393 / 35% | $2.973 / 41% | $4.887 / 38% | $6.228 / 42% |
| Operating loss | $3.955 | $2.922 | $7.494 | $6.743 |
| Net loss | $3.893 | $2.867 | $8.069 | $6.454 |
| Net loss available to common stockholders | $4.198 | $3.048 | $8.604 | $6.816 |
| Basic and diluted loss per share | $0.57 | $0.41 | $1.17 | $0.95 |
At June 30, 2014, cash was $1.191, working capital was $3.616, total current assets were $13.377, and current liabilities were $9.761. Total debt was $6.902, including $0.691 current maturities; the balance sheet also showed a $0.350 warrant liability and $2.521 of accrued preferred dividends. Stockholders’ equity was $10.351.
For the six months, operating cash use was $7.257, investing cash use was $0.172, and financing cash provided was $6.981; cash declined $0.435 to $1.191. Accounts receivable increased by $3.479 in the cash flow statement. The allowance for doubtful accounts ended at $4.041, after $1.523 of provision and $1.320 of write-offs during the half-year.
Changes versus the prior comparable period
- Q2 sales declined 7% year over year; first-half sales declined 11%. Both segments reported lower first-half sales: Laboratory Services fell 11%, and Genetic Assays and Platforms fell 12%.
- Q2 gross margin fell six percentage points to 35%; first-half margin fell four points to 38%. Management attributed pressure to lower contract-laboratory volumes and fewer instrument sales.
- Q2 operating loss widened to $3.955 from $2.922. First-half operating loss widened to $7.494 from $6.743, despite lower first-half SG&A and R&D expenses.
- First-half net loss increased to $8.069 from $6.454, and cash used in operations rose to $7.257 from $5.687.
Outlook, risks, contingencies, and unusual items
- Liquidity: Management said cash and expected liquidity sources, including proceeds from the subsequent Surveyor asset sale, were sufficient for expected needs for at least 12 months. The company also disclosed a history of operating losses and inadequate operating cash generation. This expectation depended in part on the post-quarter sale and continued access to financing.
- Debt terms: A March 2014 amendment deferred term-loan principal and interest payments through March 31, 2015; payments were scheduled to resume April 1, 2015, with deferred interest capitalized. The term loan rate was 9.1%; the revolving line rate was 6.25%. Debt was secured by company assets and included financial covenants and a lender subjective acceleration clause. The company reported covenant compliance at June 30.
- Post-quarter transaction: On July 1, 2014, Transgenomic sold its Surveyor Kits technology, related assets, and inventory to Integrated DNA Technologies for $3.65 upfront and another $0.60 in four installments, with a possible additional sales-based earn-out. It retained an exclusive, royalty-free clinical-use license. The collaboration for promotion of CardioPredict expired July 1; management was evaluating commercialization options.
- Financing and dilution: In March 2014, the company issued 1,443,297 Series B preferred shares to Third Security affiliates for approximately $7.0 net proceeds. The preferred stock was initially convertible one-for-one into common shares, subject to adjustment. The financing also triggered repricing and additional issuance of certain warrants.
- Operating and reimbursement risks: Management cited lower government and private-payor reimbursement rates, competition and lengthy instrument sales cycles, customer budget constraints, and foreign-exchange exposure. The filing reported approximately $1.3 of prior-period receivables written off during the first half of 2014.
- Other items: First-half tax expense was $0.497, including approximately $0.4 related to prior periods and largely reflecting tax amortization of goodwill. A change in estimated useful lives of certain technology assets reduced Q2 operating and net loss by about $0.1. Warrant revaluation generated non-cash income of $0.250 in the first half.
- Management said pending ordinary-course claims were not expected to materially affect financial position, results, or cash flows. No material risk-factor changes from the 2013 Form 10-K were reported.
Important facts for investors to verify
- Confirm the issuer identity: this is a Transgenomic filing, whereas the request metadata names Precipio.
- Track cash burn, receivables collectability and reserve adequacy, and whether the Surveyor sale installments and any earn-out were received.
- Review the debt amendments, covenant requirements, deferred interest, and the company’s ability to meet payments beginning in April 2015.
- Assess the conversion and adjustment terms of Series B preferred stock and the warrant repricing implications for common shareholders.
- Monitor reimbursement levels, segment sales and margins, and progress in commercializing ICE COLD-PCR and CardioPredict.